Key result
Switching to atazanavir is linked to PR prolongation but not QTc changes at one month.
Why the study?
Atazanavir is preferred for HIV patients with cardiovascular comorbidities due to favorable lipid effects but has been associated with cardiac rhythm disturbances.
Does atazanavir increase QTc interval and QTc dispersion in HIV-positive patients switching from other protease inhibitors?
Comparison
QTc and QTd at baseline vs 2 hours and 1 month after atazanavir initiation
Design
Prospective single-centre open-label study
Follow-up
1 month
Authors
Loading...
No QTc change after atazanavir switch; leaves open clinical relevance of PR prolongation in larger HIV cohorts.
Cohort (n=21)
Open-label
No
Does atazanavir increase QTc interval and QTc dispersion in HIV-positive patients switching from other protease inhibitors?
Mean Difference: -1.5 (95% CI -5.5–2.46)
p-value: p=0.43
Atazanavir does not significantly prolong QTc interval or dispersion in HIV patients, but it increases the PR interval, warranting monitoring in patients with underlying heart block.
Busti et al. (2006) conducted a cohort in HIV (n=21). Atazanavir vs. Baseline was evaluated on Change in QTc interval from baseline to 1 month (MD -1.5 ms, 95% CI -5.50 to 2.46, p=0.43). Switching to atazanavir did not significantly alter the QTc interval at 1 month (mean difference -1.5 ms; 95% CI -5.50 to 2.46; P=0.43), but significantly increased the PR interval.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: